Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | GRM6 | O15303 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.32 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.32 |
| ▸ | CISD2 | Q8N5K1 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31006018 | 0.87 | ELANE (0.41) | ELANEGRM6BRD4CA2CA12 | |
| SCHEMBL18857950 | 0.87 | ELANE (0.41) | ELANEGRM6BRD4CA2CA12 | |
| SCHEMBL25836596 | 0.79 | ELANE (0.37) | ELANEGRM6BRD4CA2CISD2 | |
| SCHEMBL18675818 | 0.78 | MTNR1A (0.39) | ELANEGRM6CA2CA12CA1 | |
| SCHEMBL15867211 | 0.77 | GRM6 (0.40) | GRM6CA2CA12CA1CA9 | |
| SCHEMBL31617775 | 0.77 | ELANE (0.40) | ELANEGRM6CA2CA12CA1 | |
| SCHEMBL18089428 | 0.77 | ELANE (0.40) | ELANEBRD4CA2CA12CA1 | |
| SCHEMBL30755354 | 0.76 | GRM6 (0.42) | GRM6MTNR1AMTNR1BCISD2CYP2C9 | |
| SCHEMBL27380064 | 0.76 | GRM6 (0.42) | GRM6MTNR1AMTNR1BCISD2CYP2C9 | |
| SCHEMBL18857968 | 0.75 | KMT2A (0.37) | ELANEBRD4CA9AAK1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230287009-A1 | OXO-SUBSTITUTED COMPOUND | Sumitomo Pharma Co., Ltd. (JP) | 2023-09-14 | — | — | US | disclosed |
| US-11702431-B2 | Oxo-substituted compound | Sumitomo Pharma Co., Ltd. (JP) | 2023-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702431-B2 | Oxo-substituted compound | CYP51A1, OXA1L, O60361 | ELANE 359/4885GRM6 4086/4885BRD4 2396/4885 |
| US-20230287009-A1 | OXO-SUBSTITUTED COMPOUND | CYP51A1, OXA1L, O60361 | ELANE 359/4885GRM6 4086/4885BRD4 2396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.